BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/5/2026 7:53:11 AM | Browse: 2 | Download: 0
 |
Received |
|
2025-12-28 04:48 |
|
Peer-Review Started |
|
2025-12-30 07:26 |
|
First Decision by Editorial Office Director |
|
2026-01-06 06:35 |
|
Return for Revision |
|
2026-01-06 06:35 |
|
Revised |
|
2026-01-12 05:45 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-01-21 02:35 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-21 06:34 |
|
Articles in Press |
|
2026-01-21 06:34 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-07-22 08:41 |
|
Publish the Manuscript Online |
|
2026-08-05 07:53 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cell Biology |
| Manuscript Type |
Correspondence |
| Article Title |
Letter to the Editor: Hepatic multi-omics insights into Jiangtang tiaozhi formula for glycolipid metabolic disorders
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jia-Yu Lin, Jia-Jie Fu and Di-Guang Wen |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Di-Guang Wen, School of Medical Imaging, Hangzhou Medical College, No 8 Yikang Street, Lin’an District, Hangzhou 310059, Zhejiang Province, China. 2018110626@stu.cqmu.edu.cn |
| Key Words |
Diabetic nephropathy; Combination therapy; Sodium-glucose cotransporter 2 inhibitors; Glucagon-like peptide-1 receptor agonists; Precision medicine; Patient stratification |
| Core Tip |
Diabetic kidney disease (DKD) is a biologically heterogeneous condition, and uniform treatment strategies may not yield equivalent benefits across patients. Recent real-world evidence supports the use of combined sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists as part of a layered therapeutic approach. This commentary highlights the importance of precision patient selection, stage-specific evaluation, and mechanism-informed decision-making to optimize combination therapy. Integrating clinical phenotypes with emerging biological insights may facilitate more individualized and effective management of DKD. |
| Publish Date |
2026-08-05 07:53 |
| Citation |
Lin JY, Fu JJ, Wen DG. Letter to the Editor: Hepatic multi-omics insights into Jiangtang tiaozhi formula for glycolipid metabolic disorders. World J Diabetes 2026; 17(8): 118206
|
| URL |
https://www.wjgnet.com/1948-9358/full/v17/i8/118206.htm |
| DOI |
https://doi.org/10.4239/wjd.118206 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
